<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01170104</url>
  </required_header>
  <id_info>
    <org_study_id>CAUHHO 2009-1</org_study_id>
    <nct_id>NCT01170104</nct_id>
  </id_info>
  <brief_title>Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Phase II Trial of TACE With Sorafenib in Patients With Locally Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung-Ang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chung-Ang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the time to progression of the combination therapy of Transcatheter Arterial&#xD;
      Chemoembolization (TACE) and sorafenib in patients with previously untreated advanced or&#xD;
      metastatic hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>2 year</time_frame>
    <description>Assessments including image and laboratory studies will take place within 7days of the every TACE cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the toxicity profiles</measure>
    <time_frame>2 year</time_frame>
    <description>Clinically assessed every TACE cycle</description>
  </secondary_outcome>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE (Transcatheter arterial chemoembolization)</intervention_name>
    <description>Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Unresectable Hepatocellular carcinoma with local liver lesion treatable with TACE&#xD;
&#xD;
          2. Age &gt; 18 years.&#xD;
&#xD;
          3. ECOG Performance Status of 0 or 1.&#xD;
&#xD;
          4. Child-Pugh class A (class B could be included when Childs score is 7).&#xD;
&#xD;
          5. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          6. Subjects with at least one measurable lesion.&#xD;
&#xD;
          7. Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements to be conducted within 7 days prior to screening:&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 g/dl&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt;1,500/mm3&#xD;
&#xD;
               -  Platelet count &gt; 75,000/Î¼l&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 times the upper limit of normal&#xD;
&#xD;
               -  ALT and AST &lt; 2.5 x upper limit of normal (UNL)&#xD;
&#xD;
               -  Alkaline phosphatase &lt; 5 x ULN&#xD;
&#xD;
               -  PT-INR/PTT &lt; 1.5 x upper limit of normal&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
          8. Signed and dated informed consent before the start of specific protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cardiac disease: congestive heart failure &gt;NYHA class 2; active CAD (MI&#xD;
             more than 6 mo prior to study entry is allowed); cardiac arrythmias requiring&#xD;
             anti-arrythmic therapy( beta blockers or digoxin are permitted) or uncontrolled&#xD;
             hypertension.&#xD;
&#xD;
          2. History of HIV infection.&#xD;
&#xD;
          3. Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0)&#xD;
&#xD;
          4. Symptomatic metastatic brain or meningeal tumors (unless the patient is &gt; 6 months&#xD;
             from definitive therapy, has a negative imaging study within 4 weeks of study entry&#xD;
             and is clinically stable with respect to the tumor at the time of study entry)&#xD;
&#xD;
          5. Patients with seizure disorder requiring medication (such as steroids or&#xD;
             anti-epileptics)&#xD;
&#xD;
          6. History of organ allograft The organ allograft may be allowed as protocol specific.&#xD;
&#xD;
          7. Patients with evidence or history of uncontrolled bleeding diathesis&#xD;
&#xD;
          8. Patients undergoing renal dialysis&#xD;
&#xD;
          9. Previous or concurrent cancer that is distinct in primary site or histology from the&#xD;
             cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal&#xD;
             cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively&#xD;
             treated &gt; 3 years prior to study entry.&#xD;
&#xD;
         10. Excluded therapies and medications, previous and concomitant:&#xD;
&#xD;
               -  Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of&#xD;
                  study entry&#xD;
&#xD;
               -  Radiotherapy during study or within 3 weeks of start of study drug. (Palliative&#xD;
                  radiotherapy will be allowed). Major surgery within 4 weeks of start of study&#xD;
&#xD;
               -  Investigational drug therapy outside of this trial during or within 4 weeks of&#xD;
                  study entry&#xD;
&#xD;
               -  Prior exposure to the study drug.&#xD;
&#xD;
               -  Pregnant or breast-feeding patients. Women of childbearing potential must have a&#xD;
                  negative pregnancy test performed within 7 days of the start of treatment. Both&#xD;
                  men and women enrolled in this trial must use adequate barrier birth control&#xD;
                  measures during the course of the trial (and men for at least 3 months after last&#xD;
                  administration of study medication).&#xD;
&#xD;
               -  Substance abuse, medical, psychological or social conditions that may interfere&#xD;
                  with the patient's participation in the study or evaluation of the study results&#xD;
&#xD;
               -  Any condition that is unstable or could jeopardize the safety of the patient and&#xD;
                  their compliance in the study&#xD;
&#xD;
               -  Patients unable to swallow oral medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joung-Soon Jang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joung-Soon Jang, M.D.</last_name>
    <phone>82-2-6299-1427</phone>
    <email>alsaba@daum.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>In Gyu Hwang, M.D.</last_name>
    <phone>82-2-748-9786</phone>
    <email>higyu72@yahoo.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Dongjak</city>
        <state>Seoul</state>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joung-Soon Jang, M.D.</last_name>
      <phone>82-2-6299-1427</phone>
      <email>alsaba@daum.net</email>
    </contact>
    <contact_backup>
      <last_name>In Gyu Hwang, M.D.</last_name>
      <phone>82-2-748-9786</phone>
      <email>higyu72@yahoo.co.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Joung-Soon Jang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyung Joon Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun Woong Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>In Gyu Hwang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>July 23, 2010</study_first_submitted>
  <study_first_submitted_qc>July 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2010</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Joung-Soon Jang/Professor</name_title>
    <organization>Chung-Ang University Hospital</organization>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>TACE</keyword>
  <keyword>locally, advanced Hepatocellular Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

